Search Results

There are 1831 results for: content related to: Selection and assessment of patients treated with the novel oral anticoagulant drugs: a recommendation from the Subcommittee on Control of Anticoagulation of the Scientific and Standardisation Committee of the International Society on Thrombosis and Haemostasis

  1. Rivaroxaban: Practical Considerations for Ensuring Safety and Efficacy

    Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy

    Volume 33, Issue 11, November 2013, Pages: 1223–1245, Maureen A. Smythe, John Fanikos, Michael P. Gulseth, Ann K. Wittkowsky, Sarah A. Spinler, William E. Dager and Edith A. Nutescu

    Version of Record online : 26 MAY 2013, DOI: 10.1002/phar.1289

  2. You have free access to this content
    Rivaroxaban for the treatment and prevention of thromboembolic disease

    Journal of Pharmacy and Pharmacology

    Volume 67, Issue 8, August 2015, Pages: 1119–1132, Sotiris Antoniou

    Version of Record online : 9 JUN 2015, DOI: 10.1111/jphp.12387

  3. You have free access to this content
    Co-administration of rivaroxaban with drugs that share its elimination pathways: pharmacokinetic effects in healthy subjects

    British Journal of Clinical Pharmacology

    Volume 76, Issue 3, September 2013, Pages: 455–466, Wolfgang Mueck, Dagmar Kubitza and Michael Becka

    Version of Record online : 20 AUG 2013, DOI: 10.1111/bcp.12075

  4. You have full text access to this OnlineOpen article
    An open-label study to estimate the effect of steady-state erythromycin on the pharmacokinetics, pharmacodynamics, and safety of a single dose of rivaroxaban in subjects with renal impairment and normal renal function

    The Journal of Clinical Pharmacology

    Volume 54, Issue 12, December 2014, Pages: 1407–1420, Kenneth T. Moore, Seema Vaidyanathan, Jaya Natarajan, Jay Ariyawansa, Lloyd Haskell and Kenneth C. Turner

    Version of Record online : 3 JUL 2014, DOI: 10.1002/jcph.352

  5. You have full text access to this OnlineOpen article
    Pharmacodynamics and pharmacokinetics during the transition from warfarin to rivaroxaban: a randomized study in healthy subjects

    British Journal of Clinical Pharmacology

    Volume 78, Issue 2, August 2014, Pages: 353–363, Dagmar Kubitza, Michael Becka, Wolfgang Mück and Jöern Krätzschmar

    Version of Record online : 21 JUL 2014, DOI: 10.1111/bcp.12349

  6. You have free access to this content
    Safety, pharmacokinetics and pharmacodynamics of single/multiple doses of the oral, direct Factor Xa inhibitor rivaroxaban in healthy Chinese subjects

    British Journal of Clinical Pharmacology

    Volume 68, Issue 1, July 2009, Pages: 77–88, Xia Zhao, Peihong Sun, Ying Zhou, Yuwang Liu, Huilin Zhang, Wolfgang Mueck, Dagmar Kubitza, Richard J. Bauer, Hong Zhang and Yimin Cui

    Version of Record online : 11 FEB 2009, DOI: 10.1111/j.1365-2125.2009.03390.x

  7. You have free access to this content
    Contribution of rivaroxaban to the international normalized ratio when switching to warfarin for anticoagulation as determined by simulation studies

    British Journal of Clinical Pharmacology

    Volume 79, Issue 6, June 2015, Pages: 959–966, Hans-Ulrich Siegmund, Rolf Burghaus, Dagmar Kubitza and Katrin Coboeken

    Version of Record online : 22 MAY 2015, DOI: 10.1111/bcp.12571

  8. You have full text access to this OnlineOpen article
    Rivaroxaban – an oral, direct Factor Xa inhibitor – lessons from a broad clinical study programme

    European Journal of Haematology

    Volume 82, Issue 5, May 2009, Pages: 339–349, Sylvia Haas

    Version of Record online : 28 JAN 2009, DOI: 10.1111/j.1600-0609.2009.01230.x

  9. You have free access to this content
    Interactions between rivaroxaban and antiphospholipid antibodies in thrombotic antiphospholipid syndrome

    Journal of Thrombosis and Haemostasis

    Volume 13, Issue 7, July 2015, Pages: 1264–1273, D. R. J. Arachchillage, I. J. Mackie, M. Efthymiou, D. A. Isenberg, S. J. Machin and H. Cohen

    Version of Record online : 9 MAY 2015, DOI: 10.1111/jth.12917

  10. Rivaroxaban: a novel oral anticoagulant for the prevention and treatment of several thrombosis-mediated conditions

    Annals of the New York Academy of Sciences

    Volume 1291, Issue 1, July 2013, Pages: 42–55, Troy C. Sarich, Gary Peters, Scott D. Berkowitz, Frank Misselwitz, Christopher C. Nessel, Paul Burton, Nancy Cook-Bruns, Anthonie W.A. Lensing, Lloyd Haskell, Elisabeth Perzborn, Dagmar Kubitza, Kenneth T. Moore, Sanjay Jalota, Juergen Weber, Guohua Pan, Xiang Sun, Torsten Westermeier, Andrea Nadel, Leonard Oppenheimer and Peter M. DiBattiste

    Version of Record online : 23 MAY 2013, DOI: 10.1111/nyas.12136

  11. Rapid determination of rivaroxaban in human urine and serum using colloidal palladium surface-assisted laser desorption/ionization mass spectrometry

    Rapid Communications in Mass Spectrometry

    Volume 29, Issue 21, 15 November 2015, Pages: 1977–1983, Yu-Han Cheng, Wen-Chi Chen and Sarah Y. Chang

    Version of Record online : 28 SEP 2015, DOI: 10.1002/rcm.7308

  12. You have full text access to this OnlineOpen article
    Stroke prevention with rivaroxaban in higher-risk populations with atrial fibrillation

    International Journal of Clinical Practice

    Volume 69, Issue 7, July 2015, Pages: 743–756, H.-C. Diener, J. L. Halperin, K. Fox and G. J. Hankey

    Version of Record online : 9 APR 2015, DOI: 10.1111/ijcp.12631

  13. You have free access to this content
    Abstract

    Pharmacoepidemiology and Drug Safety

    Volume 25, Issue S3, August 2016, Pages: 3–679,

    Version of Record online : 24 AUG 2016, DOI: 10.1002/pds.4070

  14. Role of Orally Available Antagonists of Factor Xa in the Treatment and Prevention of Thromboembolic Disease: Focus on Rivaroxaban

    The Journal of Clinical Pharmacology

    Volume 50, Issue 9, September 2010, Pages: 986–1000, Jason Morell, Bridgette Sullivan, Marina Khalabuda and Brian F. McBride

    Version of Record online : 7 MAR 2013, DOI: 10.1177/0091270009355814

  15. You have free access to this content
    Effect of hepatic impairment on the pharmacokinetics and pharmacodynamics of a single dose of rivaroxaban, an oral, direct Factor Xa inhibitor

    British Journal of Clinical Pharmacology

    Volume 76, Issue 1, July 2013, Pages: 89–98, Dagmar Kubitza, Angelika Roth, Michael Becka, Abir Alatrach, Atef Halabi, Holger Hinrichsen and Wolfgang Mueck

    Version of Record online : 20 JUN 2013, DOI: 10.1111/bcp.12054

    Corrected by:

    Erratum: Corrigendum

    Vol. 76, Issue 3, 489, Version of Record online: 20 AUG 2013

  16. You have free access to this content
    Effects of renal impairment on the pharmacokinetics, pharmacodynamics and safety of rivaroxaban, an oral, direct Factor Xa inhibitor

    British Journal of Clinical Pharmacology

    Volume 70, Issue 5, November 2010, Pages: 703–712, Dagmar Kubitza, Michael Becka, Wolfgang Mueck, Atef Halabi, Haidar Maatouk, Norbert Klause, Volkmar Lufft, Dominic D. Wand, Thomas Philipp and Heike Bruck

    Version of Record online : 15 JUL 2010, DOI: 10.1111/j.1365-2125.2010.03753.x

  17. You have free access to this content
    Rivaroxaban (BAY 59-7939) – an oral, direct Factor Xa inhibitor – has no clinically relevant interaction with naproxen

    British Journal of Clinical Pharmacology

    Volume 63, Issue 4, April 2007, Pages: 469–476, Dagmar Kubitza, Michael Becka, Wolfgang Mueck and Michael Zuehlsdorf

    Version of Record online : 13 NOV 2006, DOI: 10.1111/j.1365-2125.2006.02776.x

  18. Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of Rivaroxaban—an Oral, Direct Factor Xa Inhibitor—Are Not Affected by Aspirin

    The Journal of Clinical Pharmacology

    Volume 46, Issue 9, September 2006, Pages: 981–990, Dr Dagmar Kubitza, Dr Michael Becka, Dr Wolfgang Mueck and Dr Michael Zuehlsdorf

    Version of Record online : 8 MAR 2013, DOI: 10.1177/0091270006292127

  19. You have free access to this content
    Pharmacodynamic and pharmacokinetic basics of rivaroxaban

    Fundamental & Clinical Pharmacology

    Volume 26, Issue 1, February 2012, Pages: 27–32, Reinhold Kreutz

    Version of Record online : 16 AUG 2011, DOI: 10.1111/j.1472-8206.2011.00981.x

  20. You have free access to this content
    Non-vitamin K antagonist oral anticoagulants in cardiovascular disease management: evidence and unanswered questions

    Journal of Clinical Pharmacy and Therapeutics

    Volume 39, Issue 2, April 2014, Pages: 118–135, J. W. Cheng and G. Barillari

    Version of Record online : 3 JAN 2014, DOI: 10.1111/jcpt.12122